Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L. Styles
Ibrutinib Decreases Obinutuzumab-Induced Secretion of Cytokines Associated With Infusion-Related Reactions in Patients With Cll: Analysis From the Illuminate Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Obinutuzumab Plus Bendamustine in Previously Untreated Patients With CLL: A Subgroup Analysis of the GREEN Study
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Ongoing Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
High Efficacy of Venetoclax Plus Obinutuzumab in Patients With Complex Karyotype (Ckt) and Chronic Lymphocytic Leukemia (Cll): A Prospective Analysis From the Cll14 Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Infusion Reactions Related to Infliximab Therapy Are Not Usually Associated With Drug Discontinuation
Journal of Rheumatology
Rheumatology
Allergy
Immunology
Bendamustine (B), Followed by Obinutuzumab (G) and Venetoclax (A) in Patients With Chronic Lymphocytic Leukemia (Cll): Cll2-Bag Trial of the German CLL Study Group (Gcllsg)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Significant Weight Gain in CLL Patients Treated With Ibrutinib: A Potentially Deleterious Consequence of Therapy
American Journal of Hematology
Hematology
Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Venetoclax–Obinutuzumab Elicits High Response Rates in CLL
Cancer Discovery
Oncology
Ibrutinib for Relapsed / Refractory Cll: An Update of the Uk and Ireland Analysis of Outcomes in 315 Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
